The purpose of this study is to evaluate the safety and tolerability of single doses of BLI-489 administered intravenously in healthy Japanese male subjects, and how the drug is absorbed and eliminated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
40
Unnamed facility
Tokyo, Japan
Safety as measured by the number of adverse events and serious adverse events. Tolerability will be assessed based upon the occurrence of dose limiting toxicities.
Time frame: 15 days
Pharmacokinetics as evaluated by drug concentrations in the blood and urine.
Time frame: 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.